Search Results - "Ray, Shuvra"

Simultaneous Provocation Mesenteric Angiography With Coil Embolisation and Therapeutic Gastroscopy to Treat Occult Gastrointestinal Bleeding by Meade, Susanna, van Liere, Elsa L.S.A., Diamantopoulos, Athanasios, Ray, Shuvra

“…Despite regular tranexamic acid she required multiple iron infusions, 11 admissions, 30 blood transfusions (13 units during one episode), and multiple…”
Get full text

Validation and Investigation of the Operating Characteristics of the Ulcerative Colitis Endoscopic Index of Severity by de Jong, Djuna C, Löwenberg, Mark, Koumoutsos, Ioannis, Ray, Shuvra, Mawdsley, Joel, Anderson, Simon, Sanderson, Jeremy D, Gecse, Krisztina, Ponsioen, Cyriel Y, D'Haens, Geert R, Irving, Peter M, Samaan, Mark A

“…Abstract Background The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) is a novel instrument to evaluate endoscopic disease activity. It has been…”
Get full text

The beta‐adrenoceptor agonist isoproterenol rescues acetaminophen‐injured livers through increasing progenitor numbers by Wnt in mice by Soeda, Junpei, Mouralidarane, Angelina, Ray, Shuvra, Novelli, Marco, Thomas, Steven, Roskams, Tania, Diehl, Anna Mae, Oben, Jude A.

“…Acetaminophen (APAP)‐induced acute liver injury (AILI) is a major health problem. Accumulating evidence suggests that the sympathetic nervous system (SNS)…”
Get full text

Outcomes following Serial Intragastric Balloon Therapy for Obesity and Nonalcoholic Fatty Liver Disease in a Single Centre by Oben, Jude A., Solis-Cuevas, Alessandro, Ray, Shuvra, Cordero, Paul, Gan, Jaslyn, Li, Jiawei, Nguyen, Vi, Khatib, Mai

“…Background. The incidence of nonalcoholic fatty liver disease (NAFLD) continues to parallel the rise in obesity rates. Endobariatric devices such as the…”
Get full text

Non-alcoholic fatty pancreas disease pathogenesis: a role for developmental programming and altered circadian rhythms by Carter, Rebeca, Mouralidarane, Angelina, Soeda, Junpei, Ray, Shuvra, Pombo, Joaquim, Saraswati, Ruma, Novelli, Marco, Fusai, Giuseppe, Rappa, Francesca, Saracino, Chiara, Pazienza, Valerio, Poston, Lucilla, Taylor, Paul D, Vinciguerra, Manlio, Oben, Jude A

“…Emerging evidence suggests that maternal obesity (MO) predisposes offspring to obesity and the recently described non-alcoholic fatty pancreas disease (NAFPD)…”
Get full text

Hepatic rhythmicity of endoplasmic reticulum stress is disrupted in perinatal and adult mice models of high-fat diet-induced obesity by Soeda, Junpei, Cordero, Paul, Li, Jiawei, Mouralidarane, Angelina, Asilmaz, Esra, Ray, Shuvra, Nguyen, Vi, Carter, Rebeca, Novelli, Marco, Vinciguerra, Manlio, Poston, Lucilla, Taylor, Paul D, Oben, Jude A

“…We investigated the regulation of hepatic ER stress in healthy liver and adult or perinatally programmed diet-induced non-alcoholic fatty liver disease…”
Get more information

In vitro and in vivo modeling of lipid bioaccessibility and digestion from almond muffins: The importance of the cell-wall barrier mechanism by Grassby, Terri, Mandalari, Giuseppina, Grundy, Myriam M.-L., Edwards, Cathrina H., Bisignano, Carlo, Trombetta, Domenico, Smeriglio, Antonella, Chessa, Simona, Ray, Shuvra, Sanderson, Jeremy, Berry, Sarah E., Ellis, Peter R., Waldron, Keith W.

“…•We investigated the mechanisms of lipid bioaccessibility from almond muffins.•An in vitro dynamic gastric model was used to simulate human digestion.•A pilot…”
Get full text

Depression, anxiety, and stress among inflammatory bowel disease patients during COVID‐19: A UK cohort study by Luber, Raphael P, Duff, Alexa, Pavlidis, Polychronis, Honap, Sailish, Meade, Susanna, Ray, Shuvra, Anderson, Simon H, Mawdsley, Joel, Samaan, Mark A, Irving, Peter M

“…Background and Aim Patients with chronic diseases are believed to be at increased risk of mental health conditions during the COVID‐19 pandemic. We aimed to…”
Get full text

Mechanisms and models for intestinal fibrosis in IBD by De Salvo, Carlo, Ray, Shuvra, Pizarro, Theresa T

“…Intestinal fibrosis is a common outcome in IBD leading to significant morbidity that, to date, has no effective medical treatment. Current knowledge regarding…”
Get more information

Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response by Samaan, Mark A, Birdi, Siddharth, Morales, Maria Sierra, Honap, Sailish, Tamilarasan, Aravind Gokul, Cunningham, Georgina, Koumoutsos, Ioannis, Ray, Shuvra, Mawdsley, Joel, Anderson, Simon H C, Sanderson, Jeremy, Irving, Peter M

“…BackgroundDespite the proven efficacy of vedolizumab (VDZ) for ulcerative colitis (UC) and Crohn’s disease (CD), suboptimal response is commonly encountered…”
Get full text

Tu1501: LONGER-TERM TOFACITINIB EFFECTIVENESS FOR THE TREATMENT OF ULCERATIVE COLITIS: TWO-YEAR OUTCOMES FROM A UK OBSERVATIONAL COHORT STUDY by Honap, Sailish, Sharma, Esha, Ray, Shuvra, Mawdsley, Joel, Anderson, Simon H., Samaan, Mark A., Pavlidis, Polychronis, Irving, Peter M.

Get full text

Tu1502: SAFETY ANALYSIS OF TOFACITINIB IN ULCERATIVE COLITIS: REAL-WORLD OUTCOMES FROM A THREE-YEAR UK OBSERVATIONAL COHORT STUDY by Honap, Sailish, Sharma, Esha, Ray, Shuvra, Mawdsley, Joel, Anderson, Simon H., Samaan, Mark A., Pavlidis, Polychronis, Irving, Peter M.

Get full text

Tofacitinib in Acute Severe Ulcerative Colitis—A Real-World Tertiary Center Experience by Honap, Sailish, Pavlidis, Polychronis, Ray, Shuvra, Sharma, Esha, Anderson, Simon, Sanderson, Jeremy D, Mawdsley, Joel, Samaan, Mark A, Irving, Peter M

Get full text

Su1817 FAECAL LOSS OF VEDOLIZUMAB IS ASSOCIATED WITH UC SEVERITY, LOWER SERUM VEDOLIZUMAB LEVELS AND RATES OF CLINICAL RESPONSE - RESULTS FROM THE FAVOUR STUDY by Samaan, Mark A., Cunningham, Georgina, Lim, Samuel H., Dawson, Patrick, Kottoor, Sherine Hermangild, Bheekhun, Zareen, Odukwe, Sopuluchukwu, Balachandran, Senthuran, Lee, Emma, Anderson, Simon H., Mawdsley, Joel, Ray, Shuvra, Powell, Nick, Dart, Robin J., Rawstron, Krystal, Arkir, Zehra, Irving, Peter M.

Get full text

Central role of IL-17/Th17 immune responses and the gut microbiota in the pathogenesis of intestinal fibrosis by Ray, Shuvra, De Salvo, Carlo, Pizarro, Theresa T

“…PURPOSE OF REVIEWIntestinal fibrosis is a serious, yet common, outcome in patients with inflammatory bowel disease (IBD). Despite advances in developing novel…”
Get full text

Sa1875 THERAPEUTIC THRESHOLDS FOR GOLIMUMAB SERUM CONCENTRATIONS DURING INDUCTION AND MAINTENANCE: RESULTS FROM THE GO-LEVEL STUDY by Samaan, Mark A., Cunningham, Georgina, Tamilarasan, Gokul, Hawash, Karim, Rawstron, Krystal, Beltran, Luisa, Ray, Shuvra, Mawdsley, Joel, Anderson, Simon H., Sanderson, Jeremy D., Arkir, Zehra, Irving, Peter M.

Get full text

Managing an IBD Infusion Unit During the COVID-19 Pandemic: Service Modifications and the Patient Perspective by Clough, Jennie N, Hill, Katie L, Duff, Alexa, Sharma, Esha, Ray, Shuvra, Mawdsley, Joel E, Anderson, Simon, Irving, Peter M, Samaan, Mark A

Get full text

A retrospective cohort study: pre‐operative oral enteral nutritional optimisation for Crohnʼs disease in a UK tertiary IBD centre by Meade, Susanna, Patel, Kamal V., Luber, Raphael P., O'Hanlon, Dearbhaile, Caracostea, Andra, Pavlidis, Polychronis, Honap, Sailish, Anandarajah, Cheran, Griffin, Nyree, Zeki, Sebastian, Ray, Shuvra, Mawdsley, Joel, Samaan, Mark A., Anderson, Simon H., Darakhshan, Amir, Adams, Katie, Williams, Andrew, Sanderson, Jeremy D., Lomer, Miranda, Irving, Peter M.

“…Summary Background Low‐quality evidence suggests that pre‐operative exclusive enteral nutrition (E/EN) can improve postoperative outcomes in patients with…”
Get full text

Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO‐LEVEL study by Samaan, Mark A., Cunningham, Georgina, Tamilarasan, Aravind Gokul, Beltran, Luisa, Pavlidis, Polychronis, Ray, Shuvra, Mawdsley, Joel, Anderson, Simon H., Sanderson, Jeremy D., Arkir, Zehra, Irving, Peter M.

“…Summary Background Significant associations between serum golimumab concentrations and favourable outcomes have been observed during both induction and…”
Get full text

An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch by Luber, Raphael P., O'Neill, Rhona, Singh, Sukhpreet, Sharma, Esha, Cunningham, Georgina, Honap, Sailish, Meade, Susanna, Ray, Shuvra, Anderson, Simon H., Mawdsley, Joel, Sanderson, Jeremy D., Samaan, Mark A., Arkir, Zehra, Irving, Peter M.

“…Summary Background Biologics account for a significant cost in inflammatory bowel disease (IBD) management; however, switching from infliximab originator to…”
Get full text